Proof of concept evaluation for a novel colorectal cancer therapeutic
Lead Participant:
MEDANNEX LIMITED
Abstract
‘MedAnnex is developing a novel oncology therapy based on targeting a protein known as annexin-A1, which is thought to play a role in the development of cancer. This project is a vital step in the development of an innovative cancer therapy with the potential to become a major new drug to improve patient quality of life and extend lives.’
Lead Participant | Project Cost | Grant Offer |
|---|---|---|
| MEDANNEX LIMITED | £152,298 | £ 106,609 |
Participant |
||
| ANGLIA RUSKIN UNIVERSITY | £55,613 | £ 55,613 |
People |
ORCID iD |
| Fiona Dempsey (Project Manager) |